Robbins LLP Reminds Intellia Therapeutics, Inc. (NTLA) Investors with Large Losses to Contact the Firm to Learn How They Can Recover for Their Losses

Core Viewpoint - A class action has been filed against Intellia Therapeutics, Inc. for allegedly misleading investors regarding the viability of its drug candidate NTLA-3001, which is intended for treating alpha-1 antitrypsin deficiency-associated lung disease [1][2]. Allegations - The complaint claims that during the class period, Intellia provided investors with optimistic information about its Phase 1/2 study for NTLA-3001, including expectations to dose the first patient in the second half of 2024 [2]. - It is alleged that Intellia failed to disclose that demand for viral-based editing was declining as non-viral delivery methods gained traction due to their cost-effectiveness and efficiency, making NTLA-3001 an inefficient program for the company [2]. Revelation of Truth - On January 9, 2025, Intellia announced a reorganization, halting all NTLA-3001 research and studies, and disclosed a workforce reduction of 27% in 2025, leading to a 15% decline in the company's stock price [3]. Next Steps for Shareholders - Shareholders may be eligible to participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiff, although participation is not required for recovery [4]. About Robbins LLP - Robbins LLP is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses and improve corporate governance since 2002 [5].